Results 241 to 248 of about 45,526 (248)

Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant bcr-abl positive lymphoid malignancies

Journal of Clinical Oncology, 2005
3015 Background: AMN107, a novel aminopyrimidine ATP-competitive inhibitor of Bcr-Abl. AMN107, is 10- to 50-fold more potent than imatinib against Bcr-Abl expressing cell lines, and is effective against most cell lines expressing imatinib-resistant Bcr-Abl mutants.
O. Ottmann, F. Giles, B. Wassmann, A. Hochhaus, P. Rae, M. Beran, M. Albitar, L. Alland, M. Dugan, H. Kantarjian   +9 more
openaire   +1 more source

bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leukemia, 1988
Tumor-specific alterations in oncogenes are thought to play a central role in the development of cancer. An example is the consistent fusion of the bcr gene to the c-abl oncogene on the Ph chromosome in CML. The Ph chromosome can also be observed in ALL. About 50% of Ph+ ALL cases, in contrast to CML, do not exhibit chromosomal breakpoints in the major
Hermans, A., Gow, J., Selleri, L., von Lindern, M., Hagemeijer, A., Wiedemann, L. M., Grosveld, G.   +6 more
openaire   +2 more sources

Advances in BCR/ABL positive ALL

ADVANCES IN CELL AND GENE THERAPY, 2019
Netanel A. Horowitz, Jacob M. Rowe
openaire   +1 more source

Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia.

Experimental hematology, 1996
Remission marrow from patients with BCR-ABL+ acute lymphoblastic leukemia (ALL) achieving clinical remission (CR) after induction or consolidation chemotherapy according to the German multicenter adult ALL (GMALL) protocol showed high titers of residual BCR-ABL+ cells.
H, Martin, J, Atta, P, Zumpe, M, Eder, S, Elsner, C, Rode, B, Wassmann, J, Bruecher, D, Hoelzer   +8 more
openaire   +1 more source

Imatinib for relapsed BCR/ABL positive leukemias.

Annals of hematology, 2003
O G, Ottmann, B, Wassmann, D, Hoelzer
openaire   +1 more source

Bcl2 as a therapeutic target in BCR-ABL positive ALL

Klinische Pädiatrie, 2014
AK Elder, M Scherr, O Heidenreich, M Eder   +3 more
openaire   +1 more source

MYC-MAX HETERODYMER POSITIVELY REGULATES BCR AND BCR/ABL EXPRESSION

2015
Magistroni, Vera, Nitesh Sharma, Piazza, Rocco, Mezzatesta, Caterina, Passerini, Carlo Gambacorti   +4 more
openaire   +1 more source

New tyrosine kinase inhibitors in bcr-abl positive leukemia

2006
openaire   +1 more source